Pharmacyclics earns $50M milestone on ibrutinib trial start

Pharmacyclics Inc. (NASDAQ:PCYC) will receive a $50 million payment from partner Janssen Biotech Inc. after the Johnson & Johnson (NYSE:JNJ) unit enrolled the fifth patient in the Phase II SPARK trial...